Form 4: Adverum Biotechnologies Director Increases Stake in Company
SEC Form 4 Filing
Director Braden Michael Leonard reports purchasing additional shares of Adverum Biotechnologies, Inc., increasing his direct and indirect holdings.
Summary
- On March 26, 2025, Director Braden Michael Leonard purchased 20,407 shares of Adverum Biotechnologies (ADVM) at a weighted average price of $5.0395 per share, increasing his direct holdings to 125,207 shares.
- On March 27, 2025, Leonard purchased an additional 16,593 shares at a weighted average price of $5.1883 per share, bringing his direct holdings to 141,800 shares.
- Leonard also indirectly owns 2,722,761 shares through BML Investment Partners, L.P., where BML Capital Management, LLC serves as the general partner and Leonard is the managing member.
- Leonard disclaims beneficial ownership of the shares held by BML Investment Partners, L.P., except to the extent of his pecuniary interest.
- An amendment was filed to correct a clerical error, clarifying that the shares purchased on March 27, 2025, were acquired ('A') rather than disposed of.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the impact is limited without additional context about the company's performance.
Positives
- The director's purchase of additional shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that those with the most knowledge of the company's prospects are optimistic about its future. However, it's important to consider the size of the purchases relative to the director's overall holdings and the company's market capitalization.
Stakeholder Impact
- Shareholders may view the director's purchase as a positive signal.
- The increased stake could align the director's interests more closely with those of other shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/26/2025 | Director purchased 20,407 shares at $5.0395 per share. |
| 03/27/2025 | Director purchased 16,593 shares at $5.1883 per share. |
| 04/28/2025 | Date of the Form 4 filing. |
Keywords
Adverum Biotechnologies, ADVM, insider trading, Form 4, share purchase, director, Leonard, BML Investment Partners
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.